Cefotetan in the treatment of obstetric and gynecologic infections
The efficacy, tolerance, and safety of cefotetan—a new 7-α-methoxy cephalosporin—was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was eq...
Gespeichert in:
| Veröffentlicht in: | American journal of obstetrics and gynecology 1986-04, Vol.154 (4), p.946-950 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 950 |
|---|---|
| container_issue | 4 |
| container_start_page | 946 |
| container_title | American journal of obstetrics and gynecology |
| container_volume | 154 |
| creator | Poindexter, Alfred N. Sweet, Richard Ritter, Marcella |
| description | The efficacy, tolerance, and safety of cefotetan—a new 7-α-methoxy cephalosporin—was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit. |
| doi_str_mv | 10.1016/0002-9378(86)90495-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76796229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002937886904953</els_id><sourcerecordid>14623608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-8da91b427fd307a92a5194d195b6d0c48acba0ec37e86528ae54ae5d89d6de9b3</originalsourceid><addsrcrecordid>eNqFkE9LAzEQxYMotVa_gcKeRA-ryWY3m1wELf6Dghc9h2wyWyNtokkq9NubtaVHPQzD8N6bYX4InRJ8RTBh1xjjqhS05RecXQpci6ake2hMsGhLxhnfR-Od5RAdxfgxjJWoRmhEG9KIWozR3RR6nyApV1hXpHcoUgCVluBS4fvCdzGLwepCOVPM1w60X_h5nq3rQSfrXTxGB71aRDjZ9gl6e7h_nT6Vs5fH5-ntrNSU81RyowTp6qrtDcWtEpVqiKgNEU3HDNY1V7pTGDRtgbOm4gqaOpfhwjADoqMTdL7Z-xn81wpikksbNSwWyoFfRdmyVrD8379GUrOKMsyzsd4YdfAxBujlZ7BLFdaSYDkwlgMxOQCUnMlfxpLm2Nl2_6pbgtmFtlCzfrPRIdP4thBk1BacBmNDZiaNt38f-AHKD4tR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14623608</pqid></control><display><type>article</type><title>Cefotetan in the treatment of obstetric and gynecologic infections</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Poindexter, Alfred N. ; Sweet, Richard ; Ritter, Marcella</creator><creatorcontrib>Poindexter, Alfred N. ; Sweet, Richard ; Ritter, Marcella</creatorcontrib><description>The efficacy, tolerance, and safety of cefotetan—a new 7-α-methoxy cephalosporin—was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit.</description><identifier>ISSN: 0002-9378</identifier><identifier>EISSN: 1097-6868</identifier><identifier>DOI: 10.1016/0002-9378(86)90495-3</identifier><identifier>PMID: 3515949</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; antibiotics ; Bacterial Infections - drug therapy ; Bacterial Infections - metabolism ; Cefotetan ; Cefoxitin - therapeutic use ; Cephamycins - metabolism ; Cephamycins - therapeutic use ; Clinical Trials as Topic ; Drug Tolerance ; endometritis ; Female ; Genital Diseases, Female - drug therapy ; Genital Diseases, Female - metabolism ; Humans ; Microbial Sensitivity Tests ; Middle Aged ; Moxalactam - therapeutic use ; pelvic inflammatory disease ; Pregnancy ; Pregnancy Complications, Infectious - drug therapy ; Pregnancy Complications, Infectious - metabolism ; Random Allocation</subject><ispartof>American journal of obstetrics and gynecology, 1986-04, Vol.154 (4), p.946-950</ispartof><rights>1986</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-8da91b427fd307a92a5194d195b6d0c48acba0ec37e86528ae54ae5d89d6de9b3</citedby><cites>FETCH-LOGICAL-c388t-8da91b427fd307a92a5194d195b6d0c48acba0ec37e86528ae54ae5d89d6de9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0002937886904953$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3515949$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poindexter, Alfred N.</creatorcontrib><creatorcontrib>Sweet, Richard</creatorcontrib><creatorcontrib>Ritter, Marcella</creatorcontrib><title>Cefotetan in the treatment of obstetric and gynecologic infections</title><title>American journal of obstetrics and gynecology</title><addtitle>Am J Obstet Gynecol</addtitle><description>The efficacy, tolerance, and safety of cefotetan—a new 7-α-methoxy cephalosporin—was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit.</description><subject>Adult</subject><subject>antibiotics</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - metabolism</subject><subject>Cefotetan</subject><subject>Cefoxitin - therapeutic use</subject><subject>Cephamycins - metabolism</subject><subject>Cephamycins - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Drug Tolerance</subject><subject>endometritis</subject><subject>Female</subject><subject>Genital Diseases, Female - drug therapy</subject><subject>Genital Diseases, Female - metabolism</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Moxalactam - therapeutic use</subject><subject>pelvic inflammatory disease</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - drug therapy</subject><subject>Pregnancy Complications, Infectious - metabolism</subject><subject>Random Allocation</subject><issn>0002-9378</issn><issn>1097-6868</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9LAzEQxYMotVa_gcKeRA-ryWY3m1wELf6Dghc9h2wyWyNtokkq9NubtaVHPQzD8N6bYX4InRJ8RTBh1xjjqhS05RecXQpci6ake2hMsGhLxhnfR-Od5RAdxfgxjJWoRmhEG9KIWozR3RR6nyApV1hXpHcoUgCVluBS4fvCdzGLwepCOVPM1w60X_h5nq3rQSfrXTxGB71aRDjZ9gl6e7h_nT6Vs5fH5-ntrNSU81RyowTp6qrtDcWtEpVqiKgNEU3HDNY1V7pTGDRtgbOm4gqaOpfhwjADoqMTdL7Z-xn81wpikksbNSwWyoFfRdmyVrD8379GUrOKMsyzsd4YdfAxBujlZ7BLFdaSYDkwlgMxOQCUnMlfxpLm2Nl2_6pbgtmFtlCzfrPRIdP4thBk1BacBmNDZiaNt38f-AHKD4tR</recordid><startdate>19860401</startdate><enddate>19860401</enddate><creator>Poindexter, Alfred N.</creator><creator>Sweet, Richard</creator><creator>Ritter, Marcella</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19860401</creationdate><title>Cefotetan in the treatment of obstetric and gynecologic infections</title><author>Poindexter, Alfred N. ; Sweet, Richard ; Ritter, Marcella</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-8da91b427fd307a92a5194d195b6d0c48acba0ec37e86528ae54ae5d89d6de9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>antibiotics</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - metabolism</topic><topic>Cefotetan</topic><topic>Cefoxitin - therapeutic use</topic><topic>Cephamycins - metabolism</topic><topic>Cephamycins - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Drug Tolerance</topic><topic>endometritis</topic><topic>Female</topic><topic>Genital Diseases, Female - drug therapy</topic><topic>Genital Diseases, Female - metabolism</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Moxalactam - therapeutic use</topic><topic>pelvic inflammatory disease</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - drug therapy</topic><topic>Pregnancy Complications, Infectious - metabolism</topic><topic>Random Allocation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poindexter, Alfred N.</creatorcontrib><creatorcontrib>Sweet, Richard</creatorcontrib><creatorcontrib>Ritter, Marcella</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of obstetrics and gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poindexter, Alfred N.</au><au>Sweet, Richard</au><au>Ritter, Marcella</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cefotetan in the treatment of obstetric and gynecologic infections</atitle><jtitle>American journal of obstetrics and gynecology</jtitle><addtitle>Am J Obstet Gynecol</addtitle><date>1986-04-01</date><risdate>1986</risdate><volume>154</volume><issue>4</issue><spage>946</spage><epage>950</epage><pages>946-950</pages><issn>0002-9378</issn><eissn>1097-6868</eissn><abstract>The efficacy, tolerance, and safety of cefotetan—a new 7-α-methoxy cephalosporin—was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>3515949</pmid><doi>10.1016/0002-9378(86)90495-3</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9378 |
| ispartof | American journal of obstetrics and gynecology, 1986-04, Vol.154 (4), p.946-950 |
| issn | 0002-9378 1097-6868 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76796229 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult antibiotics Bacterial Infections - drug therapy Bacterial Infections - metabolism Cefotetan Cefoxitin - therapeutic use Cephamycins - metabolism Cephamycins - therapeutic use Clinical Trials as Topic Drug Tolerance endometritis Female Genital Diseases, Female - drug therapy Genital Diseases, Female - metabolism Humans Microbial Sensitivity Tests Middle Aged Moxalactam - therapeutic use pelvic inflammatory disease Pregnancy Pregnancy Complications, Infectious - drug therapy Pregnancy Complications, Infectious - metabolism Random Allocation |
| title | Cefotetan in the treatment of obstetric and gynecologic infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T16%3A12%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cefotetan%20in%20the%20treatment%20of%20obstetric%20and%20gynecologic%20infections&rft.jtitle=American%20journal%20of%20obstetrics%20and%20gynecology&rft.au=Poindexter,%20Alfred%20N.&rft.date=1986-04-01&rft.volume=154&rft.issue=4&rft.spage=946&rft.epage=950&rft.pages=946-950&rft.issn=0002-9378&rft.eissn=1097-6868&rft_id=info:doi/10.1016/0002-9378(86)90495-3&rft_dat=%3Cproquest_cross%3E14623608%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14623608&rft_id=info:pmid/3515949&rft_els_id=0002937886904953&rfr_iscdi=true |